| Literature DB >> 10579840 |
D Nagarathnam1, S W Miao, B Lagu, G Chiu, J Fang, T G Murali Dhar, J Zhang, S Tyagarajan, M R Marzabadi, F Zhang, W C Wong, W Sun, D Tian, J M Wetzel, C Forray, R S Chang, T P Broten, R W Ransom, T W Schorn, T B Chen, S O'Malley, P Kling, K Schneck, R Bendesky, C M Harrell.
Abstract
Dihydropyrimidinones such as compound 12 exhibited high binding affinity and subtype selectivity for the cloned human alpha(1a) receptor. Systematic modifications of 12 led to identification of highly potent and subtype-selective compounds such as (+)-30 and (+)-103, with high binding affinity (K(i) = 0.2 nM) for alpha(1a) receptor and greater than 1500-fold selectivity over alpha(1b) and alpha(1d) adrenoceptors. The compounds were found to be functional antagonists in human, rat, and dog prostate tissues. Compound (+)-103 exhibited excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs (K(b)(DBP)/K(b)(IUP) = 40) suggesting uroselectivity for alpha(1a)-selective compounds.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10579840 DOI: 10.1021/jm990200p
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446